Table 3.

The Cox univariate and multivariate analyses of mCRC patients receiving third-line therapy

Factor	PFS3				OS3
	P	HR	95%CI	P		HR	95%CI
Cox univariate analyses
Gender (Male vs. Female)	0.097	0.766	0.559–1.049	0.367		0.858	0.616–1.196
Age (< 60 vs. ≥60)	0.596	0.921	0.679–1.249	0.500		0.895	0.647–1.237
Location of primary tumor
Transverse colon vs. Ascending colon	0.532	1.243	0.628–2.460	0.246		0.648	0.312–1.347
Descending colon vs. Ascending colon	0.846	1.070	0.542–2.112	0.690		1.154	0.571–2.330
Sigmoid colon vs. Ascending colon	0.933	1.018	0.675–1.535	0.814		0.952	0.630–1.438
Rectum vs. Ascending colon	0.860	1.043	0.651–1.671	0.139		0.695	0.429–1.126
Pathologic differentiation
Well vs. Poorly	0.628	0.811	0.349–1.889	0.779		0.886	0.382–2.058
Moderately vs. Poorly	0.336	1.238	0.801–1.916	0.363		0.808	0.510–1.279
Resection of primary tumor
Palliative vs. Radical resection	0.867	1.029	0.733–1.446	0.064		1.403	0.981–2.007
None vs. Radical resection	0.011	1.730	1.131–2.645	0.010		1.816	1.155–2.854
RAS/RAF status (Wild-type vs. Mutant-type)	0.563	0.904	0.644–1.271	0.011		0.615	0.424–0.893
Number of metastatic organs at third-line treatment	0.456	1.074	0.890–1.296	0.281		1.121	0.911–1.381
PFS of front-line treatment (PFS1 + PFS2 > 10.6 m vs. ≤10.6 m)	0.003	0.595	0.423–0.835	0.036		0.686	0.482–0.976
Third-line treatment (Anti-angiogenic drugs vs. Chemotherapy ± targeted drugs)	0.001	1.863	1.284–2.703	0.000		2.203	1.514–3.206
Third-line chemotherapy (Re-challenge vs. New regimens)	0.790	1.051	0.730–1.512	0.355		1.208	0.809–1.803
Third-line targeted drugs (Re-challenge vs. New drugs)	0.174	1.308	0.888–1.926	0.146		1.359	0.898–2.055
Previous use of anti-angiogenic therapy (Yes vs. No)	0.925	1.021	0.666–1.564	0.584		0.882	0.564–1.381
Later-line treatment (Yes vs. No)	-	-	-	0.000		0.496	0.349–0.703
Cox multivariate analyses
Resection of primary tumor
Palliative vs. Radical resection	0.977	0.995	0.697–1.419	0.728		1.073	0.722–1.594
None vs. Radical resection	0.062	1.539	0.978–2.421	0.277		1.310	0.805–2.132
RAS/RAF status (Wild-type vs. Mutant-type)	-	-	-	0.021		0.613	0.405–0.929
PFS of front-line treatment (PFS1 + PFS2 > 10.6 m vs. ≤10.6 m)	0.036	0.685	0.480–0.976	0.030		0.670	0.467–0.963
Third-line treatment (Anti-angiogenic drugs vs. Chemotherapy ± targeted drugs)	0.029	1.598	1.049–2.435	0.001		2.004	1.313–3.059
Later-line treatment (Yes vs. No)	-	-	-	0.004		0.564	0.380–0.836

HR: Hazard ratio, CI: confidence interval, PFS: Progression-free survival, OS: Overall survival